Mantle Cell Lymphoma: NCI Study Demonstrates Good Benefits for BiovaxID(R) Cancer Vaccine

While a press release, encouraging results from a new drug BiovaxID (R) trial for mantle cell lymphoma. The drug, in the form of an immunotherapy vaccine (following Rituximab and chemo), stimulates T-cell immune responses, with improved survival and time-to-next treatment benefits. Still at Phase II but encouraging.

NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID(R) Cancer Vaccine  – MarketWatch.


What do you think?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s